Recent commentary on high response rates and full enrollment in Immunovant (IMVT)'s Phase 2 rheumatoid arthritis trial for IMVT-1402 has focused investor attention on whether this engagement in a difficult-to-treat population justifies the stock’s recent momentum.

That trial update lands on top of solid momentum in the stock, with a 30 day share price return of 9.23% and a 1 year total shareholder return of 88.83%. This points to building enthusiasm around Immunovant’s pipeline story.

If this kind of trial driven move has your attention, it could be a good moment to look across other healthcare AI opportunities using the 39 healthcare AI stocks

With shares up 9.23% over 30 days and 88.83% over 1 year, enthusiasm is clear. However, with a US$31.61 price against a US$45.76 target, should you see upside potential here, or assume the market is already pricing in future growth?

Most Popular Narrative: 23.1% Undervalued

Analysts following the most popular narrative see fair value at $41.12, comfortably above Immunovant’s last close at $31.61. This view places significant emphasis on IMVT-1402’s long term potential.

The fully enrolled D2T RA study for IMVT-1402, upsized to 170 patients, reflects strong physician and patient engagement that could support broader adoption in difficult to treat autoimmune populations over time, which would be most visible in revenue growth if late stage data are supportive.

Want to see what kind of revenue ramp, margin profile and future earnings multiple sit behind that FAIR value? The narrative leans on ambitious long range profit assumptions and a premium P/E usually reserved for stand out growth stories.

Result: Fair Value of $41.12 (UNDERVALUED)

However, this depends on IMVT-1402 delivering on high expectations and on access to funding, with trial setbacks or extra dilution both capable of reversing the situation.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Optimistic about the story so far? Take a moment to review the underlying data and sentiment for yourself, including at least 5 important warning signs

Looking for more investment ideas?

If Immunovant has sharpened your focus, do not stop there. Broaden your watchlist with other potential opportunities that could fit different roles in your portfolio.

• Target stronger returns potential by scanning for quality companies trading below their estimated worth using the 46 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies built around reliable payouts and higher yields through the 9 dividend fortresses.
• Prioritize resilience by focusing on companies with robust finances and clean balance sheets using the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.